Iveric bio will delay enrollment in its second pivotal clinical trial for Zimura due to the coronavirus global pandemic, the company announced in a press release.
Zimura (avacincaptad pegol), a novel complement C5 inhibitor, is being developed for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
“In light of the COVID-19 pandemic and out of an abundance of caution for the safety and well-being of our elderly patients and participating physicians and their staffs, we have decided to delay the initiation of enrollment in our second pivotal (Read more...)
Uncategorized